Pancreatic Cancer Research

ResearcherUniversity of VirginiaActive in the last 2 years

Kimberly A. Kelly

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1146-3137; OpenAlex author ID A5089175484; NIH RePORTER profile ID 7258599. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
5
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 1 grant · 2013: 3 papers, 1 grant · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 grant · 2018: none · 2019: 2 grants · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer. Last author DOI 10.3389/fimmu.2026.1894080↗
  2. Imaging Cell Surface Plectin in PDAC Patients - A First-In-Human Phase 0 Study Report. Last author DOI 10.1007/s11307-025-02001-8↗
  3. A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ph16030389↗
  4. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biochi.2020.11.018↗
  5. Challenges of Pancreatic Cancer. Last author DOI 10.1097/ppo.0000000000000109↗
  6. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Co-author DOI 10.1002/pmic.201200319↗
  7. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Last author DOI 10.1073/pnas.1309720110↗
  8. Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer. Last author DOI 10.3389/fonc.2013.00084↗

Grants 5

  1. Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again R01CA216879↗
  2. Taste Receptor Family 2 Member 9 as a novel target for imaging Cancer Associated Fibroblasts in pancreatic cancer R21CA231196↗
  3. Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer R01CA168712↗
  4. Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo R01EB010023↗
  5. Development of Molecularly Targeted Imaging Agents for Early Detection of PDAC R01CA137071↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julien Dimastromatteo · 2 shared papers, 2015–2025 · strength 0.44
  2. Julie L Sutcliffe · 1 shared grant, 2019 · strength 0.40
  3. Reid B. Adams · 1 shared paper, 2025 · strength 0.37
  4. Lisa M. Coussens · 1 shared paper, 2026 · strength 0.29
  5. Matthew J Lazzara · 1 shared paper, 2026 · strength 0.29
  6. Cody L. Wolf · 1 shared paper, 2026 · strength 0.29
  7. Brent A French · 1 shared paper, 1 shared grant, 2013–2017 · strength 0.27
  8. Craig D. Logsdon · 1 shared paper, 1 shared grant, 2013–2017 · strength 0.27
  9. Ru Chen · 3 shared papers, 2013–2021 · strength 0.23
  10. Teresa A. Brentnall · 3 shared papers, 2013–2021 · strength 0.23
  11. Sheng Pan · 3 shared papers, 2013–2021 · strength 0.23
  12. Lindsey T. Brinton · 1 shared paper, 2023 · strength 0.18
  13. Jessica Shuk-Chun Hung · 1 shared paper, 2023 · strength 0.18
  14. Howard C. Crawford · 1 shared paper, 2023 · strength 0.18
  15. NABEEL El-BARDEESY · 1 shared grant, 2013 · strength 0.15
  16. Hongyu Wang · 1 shared paper, 2021 · strength 0.14
  17. David W. Dawson · 1 shared paper, 2021 · strength 0.14
  18. Jacob L. Houghton · 1 shared paper, 2015 · strength 0.07
  19. Jason Stuart Lewis · 1 shared paper, 2015 · strength 0.07
  20. Prasad R. Konkalmatt · 1 shared paper, 2013 · strength 0.04
  21. Soo Jung Shin · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.